Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Botulinum toxin treatment improves dysphagia in patients with oculopharyngeal muscular dystrophy and sporadic inclusion body myositis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Causes of symptom dissatisfaction in patients with generalized myasthenia gravis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Diagnostic interest of whole-body MRI in early- and late-onset LAMA2 muscular dystrophies: a large international cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prediagnosis epilepsy and survival in patients with glioma: a nationwide population-based cohort study from 2009 to 2018

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Three novel FHL1 Variants cause a mild Phenotype of Emery-Dreifuss Muscular Dystrophy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Complement C4 Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Novel truncating variants in FGD1 detected in two Danish families with Aarskog-Scott syndrome and myopathic features

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: Dysphagia can be troublesome in sporadic inclusion body myositis (sIBM) and oculopharyngeal muscular dystrophy (OPMD), but no established treatment exists. Cricopharyngeal muscle botulinum toxin injection has at case level been reported to be effective. We evaluated safety and efficacy of botulinum toxin injections in the cricopharyngeal muscle in patients with dysphagia due to sIBM or OPMD.

METHODS: Participants were included from our outpatient clinic. Cricopharyngeal constriction was confirmed by laryngoscopy. After EMG confirmation of needle placement in the cricopharyngeal muscle, botulinum toxin A was injected in awake patients. An individualized dose of 5-10 units of botulinum toxin A was applied initially and titrated up a maximum of 3 times. Outcome measures were change in dysphagia questionnaire, timed cold-water swallow test and subjective dysphagia status (worse, unchanged, improved). Due to the need for individualized dosing and a limited number of available patients, an uncontrolled, un-blinded design was used.

RESULTS: Thirteen patients, 3 with OPMD, received at least 1 injection. In the dysphagia questionnaire, all but 2 subjects, none with subjective worsening, improved (p < 0.001). Subjectively, seven felt an improvement, 4 no change and 2 a worsening. No overall change was seen the timed cold-water swallow test. No serious adverse events were observed.

CONCLUSION: Botulinum toxin injection of the cricopharyngeal muscle in patients with OPMD and sIBM had a beneficial effect on dysphagia in most of the treated patients. Two of 13 patients experienced a temporary worsening not reflected in dysphagia score. Limitations are the un-blinded and un-randomized design and subjective assessments methods.

PROSPECTIVE TRIAL REGISTRATION: EudraCT-number: 2014-002210-23.

OriginalsprogEngelsk
TidsskriftJournal of Neurology
Vol/bind269
Udgave nummer8
Sider (fra-til)4154-4160
Antal sider7
ISSN0340-5354
DOI
StatusUdgivet - aug. 2022

Bibliografisk note

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

ID: 79737573